ODP’s breakthrough technology platform, the ‘Pharmacy on Demand’ (PoD)TM, is the world’s most advanced, miniaturized, and automated suite of pharmaceutical manufacturing systems.
ODP is developing a range of new technologies to transform manufacturing along the entire pharmaceutical life cycle—everything from starting materials and active pharmaceutical ingredients (APIs) to formulated sterile injectables.
ODP not only manufactures drugs—we also design and manufacture components of our platform (hardware and software) to enable our end-to-end capability.
The PoD platform has produced 16 precursors, 22 APIs, five finished drug tablets, and three sterile injectable formulations.
PoD is an agile, end-to-end system that can be customized in just hours to make various products—from precursors to final formulated drugs.
PoD will incorporate advanced in-process monitoring utilizing propriety state-of-the-art quality management systems that enable real-time, “every” dose monitoring. This technology will surpass the quality standards currently required in traditional batch processing.
Revolutionizing where and how medicines are made.
When a local or regional crisis strikes—pandemic, natural disaster, supply chain shortage or disruption— PoD can provide a responsive, customizable and fast solution.
Medicines can be manufactured when and where they are needed, from the front lines to fire stations, from hospitals to remote villages.
A distributed network of PoDs will reduce vulnerabilities associated with an over-reliance on centralized manufacturing and processing models.
PoD offers greater volume versatility over traditional batch manufacturing. It can make 100s to millions of doses depending on the need.
PoD will improve the reliability and responsiveness of our medicine supply chain.
PoD can stabilize pricing by enabling ‘just in time’ manufacturing capability that reduces the need to stockpile large supplies of medicines and is more responsive to surges in demand.
PoD is uniquely designed to meet the needs of the precision medicine frontier and to address orphan and rare diseases. As medicines become more personalized, the PoD technology can provide a cost-effective manufacturing option.
PoD is a greener pharmaceutical manufacturing solution with the potential to reduce waste by manufacturing what is needed when it is needed and reducing waste throughout the product lifecycle (e.g. storage, distribution, expirations), creating a positive environmental impact.
This ‘Made in America’ manufacturing capability and strategic asset will mitigate drug shortages during both peacetime and crises, improve our readiness to biomedical threats, create new, high-paying U.S. jobs, reduce U.S. dependence on foreign manufacturers, advance the U.S.’s innovation prowess, and usher in a technology revolution that will leapfrog our legacy 19th century industrial manufacturing processes.